Skip to main content

Table 1 Baseline characteristics

From: Acid–base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease

Parameter Propensity score-matched controls (n = 178) Liver cirrhosis (n = 178) p value
Age, years (IQR) 65 (55–75) 55 (48–62) < 0.01
Male gender, n (%) 79 (44%) 82 (46%) 0.837
SOFA score (IQR) 12 (8–16) 13 (10–16) 0.084
SAPS II score (IQR) 59 (44–72) 62 (44–79 0.101
CLIF-SOFA score (IQR) 14 (11–16)  
ACLF grade
 No ACLF, n (%)   21 (12%)  
 Grade I, n (%) 27 (15%)  
 Grade II, n (%) 45 (25%)  
 Grade III, n (%) 85 (48%)  
CLIF-C ACLF score (IQR) 56.5 (48.8–63.3)  
MELD score (IQR) 26 (20–35)  
Child–Pugh score (IQR) 11 (10–13)  
Acute kidney injury, n (%) 133 (75%) 138 (78%) 0.575
Vasopressor support, n (%) 154 (87%) 158 (89%) 0.596
Mechanical ventilation, n (%) 116 (65%) 101 (57%) 0.120
Laboratory parameters
 AST, U/l (IQR) 51 (30–116) 94 (54–204) < 0.01
 ALT, U/l (IQR) 32 (19–71) 43 (24–85) 0.096
 Bilirubin, mg/dl (IQR) 1.0 (0.6–1.9) 5.4 (2.9–14.4) < 0.01
 INR (IQR) 1.2 (1.1–1.4) 1.8 (1.5–2.5) < 0.01
 Creatinine, mg/dl (IQR) 1.8 (1.2–2.7) 1.8 (1.1–3.1) 0.851
Outcome
 28-Day mortality, n (%) 54 (30%) 105 (59%) < 0.01
  1. IQR interquartile range, SOFA Sequential Organ Failure Assessment, SAPS Simplified Acute Physiology Score, CLIF-SOFA Chronic Liver Failure—Sequential Organ Failure Assessment, ACLF acute-on-chronic liver failure, CLIF-C ACLF CLIF consortium ACLF score, MELD Model of End-Stage Liver Disease, AST aspartate aminotransferase, ALT alanine aminotransferase, INR international normalized ratio